CVAC

Companies
NASDAQ
CureVac N.V.
Health Care
Price Chart
Overview

About CVAC

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Market Cap
$1.0B
Volume
3.2M
Avg. Volume
3.2M
P/E Ratio
-8.454546
Dividend Yield
0.00%
Employees
866.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.84
Moderate Correlation
Volatility
High (0.68)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for CVAC.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, CVAC shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$1.0B
Volume3.2M
P/E Ratio-8.45
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 20, 2025

PortfolioPilot Analysis

Get AI-powered insights on how CVAC fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025